Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus CapeOx vs placebo plus CapeOx in ErbB2-positive unresectable/metastatic gastric or esophagogastric adenocarcinoma
CTR20131523Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lapatinib in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by GSK. Started Nov 2013; status: completed.
02
Drugs
lapatinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20131523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131523.